SCHEMBL30775429

SCHEMBL30775429

c1ccc(-c2ccnc(OC3CCNC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.55
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
SYK P43405 1/20 0.41
HRH1 P35367 2/20 0.41
PRKCZ Q05513 1/20 0.41
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
AURKA O14965 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PRKACA P17612 1/20 0.40
ADORA2A P29274 1/20 0.40
MAPK14 Q16539 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7889387 0.77 CHRNB2 (0.54) IRAK4CHRNB2CHRNA4PRKCZHTR1A
SCHEMBL4102786 0.77 CHRNB2 (0.54) IRAK4CHRNB2CHRNA4PRKCZHTR1A
SCHEMBL30422988 0.77 CHRNB2 (0.46) IRAK4CHRNB2CHRNA4CHUKPRKCZ
SCHEMBL29003837 0.77 CHRNB2 (0.46) IRAK4CHRNB2CHRNA4CHUKPRKCZ
SCHEMBL29003833 0.77 CHRNB2 (0.46) IRAK4CHRNB2CHRNA4CHUKPRKCZ
SCHEMBL30775438 0.75 IRAK4 (0.44) IRAK4CHRNB2CHRNA4PRKCZ
SCHEMBL30775337 0.74 IRAK4 (0.45) IRAK4CHRNB2CHRNA4CHUKPRKCZ
SCHEMBL30775269 0.74 CHRNB2 (0.43) IRAK4CHRNB2CHRNA4CHUKPRKCZ
SCHEMBL30775427 0.73 NPC1 (0.49) CHRNB2CHRNA4SYKHRH1HTR1A
SCHEMBL30775250 0.72 IRAK4 (0.43) IRAK4CHRNB2CHRNA4PRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR IRAK4 4638/4885CHRNB2 3816/4885CHRNA4 4788/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR IRAK4 4638/4885CHRNB2 3816/4885CHRNA4 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.